Kythera Biopharmaceuticals Inc  

(Public, NASDAQ:KYTH)   Watch this stock  
Find more results for KYTH
74.40
-0.12 (-0.16%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 74.40 - 74.55
52 week 29.86 - 76.31
Open 74.53
Vol / Avg. 0.00/1.36M
Mkt cap 1.93B
P/E     -
Div/yield     -
EPS -4.16
Shares 25.80M
Beta     -
Inst. own 86%
Aug 5, 2015
Q2 2015 KYTHERA Biopharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 17, 2015
Allergan plc Conference Call to Discuss its Definitive Agreement to Acquire KYTHERA Biopharmaceuticals, Inc.
Jun 9, 2015
KYTHERA Biopharmaceuticals Inc at Goldman Sachs Healthcare Conference
Jun 5, 2015
KYTHERA Biopharmaceuticals Inc Annual Shareholders Meeting (Estimated)
Jun 2, 2015
KYTHERA Biopharmaceuticals Inc Annual Shareholders Meeting
May 14, 2015
KYTHERA Biopharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Q1 2015 KYTHERA Biopharmaceuticals Inc Earnings Call
May 7, 2015
Q1 2015 KYTHERA Biopharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -72.52% -97.98%
Return on average equity -100.44% -129.61%
Employees 106 -
CDP Score - -

Address

27200 Agoura Rd Ste 200
AGOURA HILLS, CA 91301-5127
United States - Map
+1-818-5874500 (Phone)
+1-818-5874591 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

KYTHERA Biopharmaceuticals, Inc. (KYTHERA) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company's initial focus is on the facial aesthetics market. The Company's product candidate is ATX101, an injectable drug in late-stage clinical development for the treatment of submental fullness associated with submental fat, which commonly presents as an undesirable double chin. ATX101 is a formulation of a purified synthetic version of deoxycholic acid. The Company has completed Phase III clinical trials for ATX101 and has made regulatory filings outside the United States, in Canada, Switzerland and Australia.

Officers and directors

Keith R. Leonard Jr. President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
John W. Smither Chief Financial Officer
Age: 62
Bio & Compensation  - Reuters
Douglas Rich Vice President - Operations
Age: 46
Bio & Compensation  - Reuters
Keith L. Klein J.D. General Counsel, Secretary
Age: 51
Bio & Compensation  - Reuters
Frederick C Beddingfield III Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
Elisabeth A. Sandoval Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
F. Michael Ball Independent Director
Age: 59
Bio & Compensation  - Reuters
Nathaniel E. David Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Dennis M. Fenton Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Francois Kress Independent Director
Age: 48
Bio & Compensation  - Reuters